Meeting
2018 ASCO Annual Meeting
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
Authors
Matt D. Galsky
Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY
Matt D. Galsky , Thomas Powles , Shengting Li , Delphine Hennicken , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03036098
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4588)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4588
Abstract #
TPS4588
Poster Bd #
413a
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
First Author: Matt D. Galsky
Poster
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
First Author: Gerard Zalcman
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
First Author: Matt D. Galsky